CReDO Science, Vashon, Washington, USA.
Washington State University, Pullman, Washington, USA.
Cannabis Cannabinoid Res. 2022 Oct;7(5):706-716. doi: 10.1089/can.2021.0058. Epub 2021 Sep 27.
Cannabigerol (CBG), and its precursor before decarboxylation, cannabigerolic acid is sometimes labeled the "mother of all cannabinoids." The purpose of the present study was to investigate reasons for use and self-reported therapeutic effects in CBG-predominant cannabis users. Usage patterns and adverse effects, including withdrawal symptoms were also explored. Cannabidiol-predominant cannabis users were recruited online to complete an online survey assessing CBG use patterns, conditions treated with CBG-predominant cannabis (containing >50% CBG), perceived efficacy, associated adverse events, and withdrawal symptoms. One hundred twenty-seven eligible participants (U.S. residents ages 21+ who reported using CBG-predominant cannabis in the past 6 months) completed the survey. Most of the samples (=65; 51.2%) reported use of CBG-predominant products solely for medical purposes (=46; 36.2% reported use for medical and recreational purposes; =8; 6.3% reported recreational use only, and =8 were missing). The most common conditions the complete sample reported using CBG to treat were anxiety (51.2%), chronic pain (40.9%), depression (33.1%), and insomnia/disturbed sleep (30.7%). Efficacy was highly rated, with the majority reporting their conditions were "very much improved" or "much improved" by CBG. Furthermore, 73.9% claimed superiority of CBG-predominant cannabis over conventional medicines for chronic pain, 80% for depression, 73% for insomnia, and 78.3% for anxiety. Forty-four percent of CBG-predominant cannabis users reported no adverse events, with 16.5% noting dry mouth, 15% sleepiness, 11.8% increased appetite, and 8.7% dry eyes. Around 84.3% reported no withdrawal symptoms, with sleep difficulties representing the most frequently endorsed withdrawal symptom (endorsed by two respondents). This is the first patient survey of CBG-predominant cannabis use to date, and the first to document self-reported efficacy of CBG-predominant products, particularly for anxiety, chronic pain, depression, and insomnia. Most respondents reported greater efficacy of CBG-predominant cannabis over conventional pharmacotherapy, with a benign adverse event profile and negligible withdrawal symptoms. This study establishes that humans are employing CBG and suggests that CBG-predominant cannabis-based medicines should be studied in randomized controlled trials.
大麻二醇 (CBG) 及其脱羧前体大麻萜酚酸有时被称为“所有大麻素的母体”。本研究旨在探讨 CBG 优势大麻使用者使用的原因和自我报告的治疗效果。还探讨了使用模式和不良反应，包括戒断症状。通过在线招募大麻二酚优势大麻使用者，完成一项在线调查，评估 CBG 使用模式、用 CBG 优势大麻（含>50% CBG）治疗的疾病、感知疗效、相关不良反应和戒断症状。127 名符合条件的参与者（美国 21 岁及以上的报告在过去 6 个月内使用 CBG 优势大麻的居民）完成了调查。 大多数样本（=65；51.2%）报告仅出于医疗目的使用 CBG 优势产品（=46；36.2%报告用于医疗和娱乐目的；=8；6.3%仅报告娱乐用途，=8 为缺失）。该完整样本报告使用 CBG 治疗的最常见疾病是焦虑症（51.2%）、慢性疼痛（40.9%）、抑郁症（33.1%）和失眠/睡眠障碍（30.7%）。疗效评价很高，大多数人报告说他们的病情通过 CBG“大大改善”或“大大改善”。此外，73.9%的人声称 CBG 优势大麻在治疗慢性疼痛方面优于常规药物，80%的人在治疗抑郁症方面，73%的人在治疗失眠方面，78.3%的人在治疗焦虑症方面。44%的 CBG 优势大麻使用者报告没有不良反应，16.5%的人报告口干，15%的人报告嗜睡，11.8%的人报告食欲增加，8.7%的人报告眼睛干涩。大约 84.3%的人报告没有戒断症状，睡眠困难是最常被报告的戒断症状（两名受访者报告）。 这是迄今为止对 CBG 优势大麻使用情况的第一项患者调查，也是第一项记录 CBG 优势产品自我报告疗效的调查，特别是在焦虑症、慢性疼痛、抑郁症和失眠方面。大多数受访者报告说，CBG 优势大麻的疗效优于常规药物治疗，不良反应轻微，戒断症状可忽略不计。这项研究表明，人类正在使用 CBG，并表明应该在随机对照试验中研究基于 CBG 优势大麻的药物。
